F-star, a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, announces the appointment of Louis Kayitalire, MD, as Chief Medical Officer, which will be effective on 17 June 2019.
June 10, 2019
· 4 min read